Abstract
performed followed by DNA methylation quantification at the promoter of the miRNA genes. Quantification of DNA methylation and miRNA expression was then performed in primary HCC tumor samples and related with clinicopathological variables.
RESULTS
miRNA profiling after DNMT knockdown in HCC cell lines revealed upregulation of miR-23, miR-25 and miR-183. After qRT-PCR confirmation and CpG island methylation quantification of these miRNAs in cell lines, further analysis in primary HCC specimens showed that hsa-miR-183 is hypermethylated in 30% of HCC (n = 40). Expression of mature miR-183 showed an inverse correlation with DNA methylation levels. In HCC cells, DNMT knockdown and 5-aza-2'-deoxycytidine treatment reduced methylation and stimulated expression of miR-183. In HCC patients, hypermethylation at hsamiR-183 promoter significantly correlates with poor survival (log-rank test P = 0.03). DNA methylation analysis in healthy liver, benign liver tumors (hepatocellular adenoma and focal nodular hyperplasia) and their corresponding adjacent tissues showed absence of hypermethylation supporting the notion that aberrant methylation at hsa-miR-183 is specific for the malignant transformation of hepatocytes.
CONCLUSION
Our data indicate that hypermethylation of hsa-miR-183 is a frequent event in HCC and potentially useful as a novel surrogate diagnostic and prognostic marker.
INTRODUCTION
A class of small non-coding RNAs with the ability to negatively regulate gene expression, named microRNA (miRNA), has been revealed to greatly contribute to tumor development and progression since the last decade [1] . Rather than completely blocking expression of the target genes, miRNAs act specifically in posttranscriptional modulation by fine-tuning of gene expression [2] . Differential expression of miRNAs has been described in almost all tumor types thus also eliciting new opportunities to utilize miRNA as a potential diagnostic or prognostic marker. Depending on their functions, miRNAs are either up-or down-regulated in cancer. After the first report revealing inactivation of miRNA genes by DNA methylation [3] , epigenetically mediated silencing of various miRNAs have been reported across different types of human cancers, including human hepatocellular carcinoma [4, 5] . DNA methylation aberrations have been shown to contribute to the early steps of malignant transformation [6] . Both miRNA expression and DNA methylation patterns display tissue specificity. Therefore, cancer profiling using those two features have successfully discriminated tumor from healthy tissues and also classified subtypes of tumors with a notable clinical relevance [7] . HCC is among the top five major types of cancer with more than 750000 new cases diagnosed each year and accounts for the third highest cancer mortality rate worldwide [8, 9] . However, knowledge about epigenetic aberrations of miRNA genes in HCC is still surprisingly limited. Only few studies have addressed DNA methylation-mediated miRNA silencing in HCC [5, 10] . Using in silico and in vitro screening, our previous study has shown frequent DNA methylation aberrations in intergenic miRNA genes and its potential value for specific detection and as a new marker for poor survival in HCC [4] . In the human genome, around 60% miRNAs are intergenic, located far away from any other known genes. The remaining 40% of miRNAs are located within introns of protein-encoding genes. Transcription of these intragenic miRNAs is likely to be regulated in the same direction as the host genes [11] . Some intragenic miRNAs have also been reported to be epigenetically inactivated in HCC [12] . To complement our previous studies, we used a comprehensive experimental screening approach to identify yet unknown hypermethylation mediated miRNA silencing in HCC. Specific DNA methyltransferase (DNMT) knockdown followed by miRNA expression profiling in HCC cell lines was performed. Upregulated miRNAs after DNMT knockdown were selected according to the presence of CpG islands in the 5 kb distance to avoid indirect and unspecific effects of DNMT knockdown. Following this strategy we identified hsa-miR-183 as a new target of aberrant DNA methylation in primary HCC specimens.
MaTeRIaLs aND MeThODs

Patient samples and cell lines
Primary tumor specimens were collected at the time of surgery from 40 patients with HCCs, 10 with hepatocellular adenoma (HCA), and 5 with focal nodular hyperplasia (FNH) operated at the Hannover Medical School Germany following a protocol approved by the local ethics committee ("Ethik-Kommission der Medizinischen Hochschule Hannover", head: Prof. Dr. Tröger). After snap froze in liquid nitrogen, the primary tissues were stored at -80 ℃ until the time of analysis. Clinical specimens were assessed by two independent pathologists following universally accepted criteria for HCC, HCA, and FNH. Morphologic classification of liver tumors and grading of hepatocellular carcinoma were performed according to recommendations as previously described by Lehmann et al [13] and Schlageter et al [14] . 
Western blot analysis
Fifteen μg of protein lysate was separated in 10% pre-cast SDS-polyacrylamide gels (Bio-RAD, Munich, Germany) and transferred onto Hybrid-P polyvinylidene difluoride membrane (Amersham Biosciences, Freiburg, Germany). Antibodies used were mouse monoclonal anti-DNMT1 antibody (IMG-261A clone 60B1220.1, Imgenex, San Diego, CA, United States), mouse monoclonal anti-β-actin antibody (ab6276 clone AC-15, Abcam, United Kingdom), and anti-mouse secondary antibody HRP (R1253HRP, Acris, Herford, Germany).
DNA and RNA extraction
Extraction of high molecular weight DNA from the fresh-snap-frozen primary specimens was performed by digestion with proteinase K (Merck, Darmstadt, Germany) followed by phenol/chloroform procedure (ROTI ® Carl Roth GmbH, Karlsruhe, Germany) following standard procedures. Total RNA was extracted 
miRNA profiling
Comprehensive miRNA expression profiling after DNMT knockdown was performed with Agilent's highperformance miRNA Microarray Platform (Release 19.0, 8x60K) using its set of optimized reagents and hardware following the supplier's instruction as previously described in detail [15] . 
Reverse transcription and quantitative real-time PCR
Bisulfite conversion and methylation analysis
For DNA methylation analysis, genomic DNA was treated with sodium bisulfite using EZ DNA Methylation Kit TM (Zymo Research, HiSS Diagnostics, Freiburg, Germany) according to the manufacturer's recommended protocol. For each PCR amplification, approximately 25 ng of the bisulfite modified DNA was used. DNA methylation analysis was performed with pyrosequencing as initially described [4] using newly designed primers as available at Table 2 . DNA methylation level for a given sample was presented as the mean of all CpG dinucleotide methylation values from two independent pyrosequencing runs. The software Pyro-Q-CpG™ (Qiagen, Hilden, Germany) was used for analyzing DNA methylation levels of each individual CpG dinucleotides. "Hypermethylated" was then defined as methylation value above mean of the adjacent liver tissue plus two times the standard deviation (Meanadj. + 2 × StD).
DAC treatment in HCC cell lines
DAC treatment in HLF, HuH7, and HepG2 cells in final concentration 100 nmol/L for 5 d was performed as initially described [4] .
Statistical analysis
Clustering analysis of the miRNA profiling after DNMT knockdown was performed using Qlucore Omics Explorer v2. 
ResULTs
Upregulated miRNAs after DNMT knockdown
Upon DNMT-1, -3A, and -3B knockdowns (Supplementary Figure 1) , several miRNAs were shown to be upregulated ( Figure 1A ). To sort out upregulation of miRNAs directly affected by demethylation due to the DNMT knockdown, we further analyzed presence of CpG island association (within 5 kb) at the miRNA gene promoters. After DNMT knockdown, hsa-miR-23 cluster, hsa-mir-25 cluster, and hsa-mir-183 cluster were shown to be upregulated by using miRNA profiling ( Figure 1A ). To show direct effects of DNMT knockdowns to alterations of DNA methylation and miRNA expression, we used HLE cells upon DNMT1 knockdown and measured methylation of hsa-miR-183 promoter and expression miR-183. DNMT1 knockdown in HLE cells led to decreased methylation at hsamiR-183 promoter (P = 0.0015) accompanied by elevated miR-183 expression (P = 0.04) ( Figure 1B ). Figure 2) . We observed differential methylation at hsa-mir-183 transcriptional start site in HCC compared to the corresponding adjacent liver tissues. Hypermethylation was demonstrated in 30% of HCC tumor samples (n = 40) (Figure 2 ).
Deregulated miRNA expression in relation with DNA methylation status
In order to evaluate the functional relevance of differential DNA methylation at hsa-mir-183 locus, we performed expression analysis of mature miR-183 in primary HCC specimens. MiR-183 was frequently downregulated in HCC and its expression negatively correlated with the methylation status ( Figure 3 ).
DNA methylation analysis in benign liver tumors and healthy liver tissues
We further analyzed DNA methylation patterns at hsamir-183 in benign liver tumor samples. Altogether 10 cases of HCA, 5 cases of FNH, their corresponding adjacent liver tissues, as well as 5 healthy liver tissues were analyzed. Aberrant methylation at hsa-mir-183 was not found in benign liver tumors and healthy liver tissues (Supplementary Figure 3) . This indicates that aberrant methylation at hsa-mir-183 might occur only during malignant transformation of hepatocytes.
Impact on HCC survival
HCC patients with hypermethylation at hsa-miR-183 locus had a significant shorter survival (log-rank test, P = 0.03; Figure 4 ). Age is not significantly different between HCC patients with and without hypermethylation indicating that the gain of methylation at hsamiR-183 is related to biological course of the disease not merely due to an increase in age. Hypermethylated samples are found more frequently in late HCC although this difference is not statistically significant.
DIsCUssION
The discovery of miRNA has brought significant improvement in the understanding of regulation of gene expression and highlighted the emerging of a novel class of regulatory molecules in gene transcription [7] . The ability of miRNAs to control gene expression post-transcriptionally reveals a complex and interrelated regulatory network of gene expression. Later, it has been also shown that miRNAs are functionally regulated by epigenetic mechanisms including DNA methylation and histone modifications [3, 4, 11] . Aberrant DNA methylation and histone modification have been suggested to be an important causal factor for deregulation of miRNA expression, especially in cancer cells.
Liver tumors comprise a range of benign, premalignant, and malignant lesions that differ in histology, etiology, clinical management, and outcome. Aberrations of both DNA methylation and miRNA expression are very specific depending on developmental stage, cell differentiation, and tissue types [5, 16, 17] . Therefore, using combination of DNA methylation and miRNA expression as clinical relevant markers is potentially of practical relevance in some complex and heterogeneous diseases including liver cancer [5] . Using an in silico screen, our previous study has revealed that aberrant DNA methylation of miRNA genes was a biological event detected only in malignant liver cells and tissues but not in adjacent tumor tissues, benign liver lesions, and in hepatocyte lines [4] . Aberrant DNA methylation at miRNA loci does not occurs at random but appears as highly organized event during the course of hepatocarcinogenesis. Therefore, DNA methylation at miRNA genes has a potential as diagnostic or prognostic marker as well as for guiding alternative adjuvant targeted therapy in HCC because some miRNAs regulated by DNA methylation play a role in modulating therapeutic responses in HCC [5, 18, 19] . In addition to the in silico screen previously done by us [4] , we performed an experimental screen by using siRNA mediated DNMT knockdown to induce re-expression of miRNA expression silenced by DNA methylation. Our experimental screen revealed that hsa-mir-183 is upregulated after DNMT knockdown. Using primary HCC specimens, aberrant DNA methylation is detected in up to 30% of total samples. DNMT1 knockdown leads to significant reduction of DNA methylation at the promoter and increased expression of mature miR-183. Downregulation of miR-183 has been previously described in several cancers such as lung cancer [20] , breast cancer [21] , or osteosarcoma [22] . Upregulation of miR-183 has also been reported in liver cancer precursors including cirrhotic and pre-malignant lesions [23] . The discrepancy of miR-183 expression in cirrhosis, premalignant liver lesions, and liver cancer might reflect the dynamic evolution during carcinogenesis since miRNAs modulate several mRNAs and transcription factors. Mature miR-183 expression in HCC can be activated by β-catenin through elevated synthesis of polycistronic transcripts of the hsamiR-182-96-182 cluster [24] . Therefore, in the presence of CTNNB1 mutations, levels of miR-183 expression might not show the expected downregulation in HCC due to complex interactions of this genetic alteration with promoter DNA methylation. In addition, upregulation of miR-183 was not correlated with survival of HCC patients [25] indicating that expression alone is not a useful prognostic marker in HCC. Our present study showed frequent aberrant DNA methylation at the promoter of hsa-miR-183. Hsamir-183 itself is an intergenic miRNA and located at chromosome 7 in a cluster together with hsa-miR-96 and hsa-miR-182. The putative transcriptional start site is predicted at 5207 bp upstream of hsa-mir-183 within a CpG island adjacent to this cluster (CpG 351). The pyrosequencing assay for the detection of DNA methylation used in this study was developed for this CpG island. Aberrant methylation of hsa-miR-183 was absent in benign liver lesions (HCAs, FNHs), adjacent liver tissues (from HCC, HCA, and FNH), as well as healthy liver tissues. This indicates that hypermethylation of hsa-miR-183 is a potential diagnostic marker to differentiate malignant liver tumor from benign lesions especially in cases where relying on histopathology alone might be difficult, for example in distinguishing HCA from well-differentiated HCC. Although involving limited numbers of HCC patients, our present study also shows that aberrant DNA methylation at hsa-miR-183 promoter is associated with poor HCC outcome. Hypermethylation of hsa-miR-183 might not be able to replace other prognostic factors commonly used to predict HCC survival, but offer an additional relevant marker to determine HCC prognosis.
COMMeNTs
Background
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited treatment options, mainly due to late detection of disease. Epigenetic alterations like DNA methylation are now recognized as important contributors to the development and progression of malignancy in humans. However, our knowledge about epigenetic alterations in HCC and their clinical relevance is still limited.
Research frontiers
Determining the clinical relevance of DNA methylation aberrations in microRNA genes and exploring the potential as new biomarker of this epigenetic aberration.
Innovations and breakthroughs
Comprehensive microRNA expression screen after DNA methyltransferase (DNMT) knockdown, avoiding the unspecific side effects of "classical epigenetic screens" using nucleotide analogues like azacytidine or aza-deoxycytidine as DNMT inhibitors. 
Peer-review
In this manuscript, Anwar et al, described the status of miR-183 methylation and related to poor survival in human HCC. In general, this is an interesting manuscript, explaining epigenetic regulation of miR-183 in HCC and its potential role as a novel surrogate and prognostic marker. 
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